Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study

doi:10.3748/wjg.v23.i22.4102

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 22

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10520)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

642

WORD

248

HTML

6371

Figures (1-2)

174

Tables (1-5)

190

Sum=7625

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1017

Download

1878

Sum=2895

Jun 14, 2017 (publication date) through Aug 29, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Jun 14, 2017; 23(22): 4102-4111
Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.4102

Table 4 Numbers of cases with liver injury events and patterns among 251 inflammatory bowel disease patients over 1 year n (%)

Liver injury event	Numbers of cases with liver injury events
			Transient	Persisting injury
	No event	Any event	1 event	2 events	3 events	4 events	5 events
ALT increase Grade 1 (0-3 × ULN)	185 (73.7)	66 (26.3)	38 (15.1)	16 (6.4)	6 (2.4)	6 (2.4)	0 (0)
ALT increase > 2 × ULN (hepatocellular injury)	235 (93.63)	16 (6.4)	12 (4.8)	1 (0.4)	1 (0.4)	1 (0.4)	1 (0.4)
ALT increase Grade 2 (> 3 × ULN)	246 (98.0)	5 (2)	4 (1.6)	1 (0.4)	0 (0)	0 (0)	0 (0)
AST increase Grade 1 (0-3 × ULN)	217 (86.45)	34 (13.5)	25 (10)	4 (1.6)	1 (0.4)	1 (0.4)	3 (1.2)
AST increase Grade 2 (> 3 × ULN)	245 (97.6)	6 (2.3)	4 (1.6)	2 (0.8)	0 (0)	0 (0)	0 (0)
ALP increase Grade 1 (0-2.5 × ULN)	232 (92.43)	19 (7.5)	11 (4.4)	3 (1.2)	4 (1.6)	0 (0)	1 (0.4)
ALP increase Grade 2 (> 2.5 × ULN)	251 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cholestasis (parallel ALP and GGT elevation)	240 (95.61)	11 (4.4)	7 (2.8)	2 (0.8)	1 (0.4)	0 (0)	1 (0.4)
Total bilirubin > 2 × ULN	250 (99.6)	1 (0.4)	1 (0.4)	0 (0)	0 (0)	0 (0)	0 (0)

ULN: Upper limit of normal; ALT: Alanine aminotransferase; AST: Aspratate aminotransferase; GGT: Gamma-glutamyl transpeptidase; ALP: Alkaline phosphatase.

Citation: Koller T, Galambosova M, Filakovska S, Kubincova M, Hlavaty T, Toth J, Krajcovicova A, Payer J. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol 2017; 23(22): 4102-4111
URL: https://www.wjgnet.com/1007-9327/full/v23/i22/4102.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i22.4102